Futura Medical plc has announced an extension of its exclusive licensing agreement with Cooper Consumer Health for the commercialization of Eroxon®, a topical, gel-based Erectile Dysfunction ("ED") treatment, in the European Economic Area, United Kingdom, and Switzerland until January 2029. The initial agreement, signed in May 2022, has been extended, with Futura remaining the Legal Manufacturer and responsible for the supply of Eroxon through its third-party contract manufacturers. The extension aims to continue the successful partnership between the two companies.
Eroxon, approved as the first pan-European topical treatment for ED available without a prescription, has seen initial launches in the UK and Belgium in March 2023, with further launches planned across Europe in 2024, including key markets such as Italy, Spain, France, and Germany. James Barder, Chief Executive Officer of Futura Medical, expressed commitment to providing treatment to those suffering from ED and highlighted the ongoing commercial roll-out of Eroxon across the world.
Bart Meermans, President of Cooper Consumer Health, emphasized the company's ambition to become a leading European consumer healthcare platform and expressed excitement about the innovation Eroxon brings to the erectile dysfunction market. The collaboration between Futura and Cooper is expected to continue with the launches of Eroxon across various markets.
Futura Medical plc, a pharmaceutical company, is developing a portfolio of innovative sexual health products based on its proprietary, transdermal DermaSys® technology. The company's flagship product, MED3000, is a topical gel formulation for the treatment of erectile dysfunction, sold in Europe and the UK under the brand name Eroxon. Futura has conducted two Phase 3 studies using MED3000 in ED, demonstrating its effectiveness and a favorable benefit versus risk profile, ideally suited for an 'Over the Counter' classification.
Cooper Consumer Health Group, on the other hand, is the largest independent self-care organization in Europe, active in the OTC consumer healthcare market with the development, manufacturing, selling, and marketing of self-care products under its own or licensed brands. The company's collaboration with Futura aims to bring Eroxon to the forefront of the erectile dysfunction market in various European markets.
This extension of the collaboration between Futura Medical and Cooper Consumer Health signifies a continued commitment to providing innovative solutions for sexual health and expanding the availability of Eroxon across Europe.